Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Short term Debt (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Short term Debt for 13 consecutive years, with $37000.0 as the latest value for Q4 2025.

  • Quarterly Short term Debt fell 68.64% to $37000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37000.0 through Dec 2025, down 68.64% year-over-year, with the annual reading at $37000.0 for FY2025, 68.64% down from the prior year.
  • Short term Debt hit $37000.0 in Q4 2025 for Guided Therapeutics, down from $79000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $1.1 million in Q2 2024 to a low of $17000.0 in Q4 2022.
  • Historically, Short term Debt has averaged $211933.3 across 4 years, with a median of $60000.0 in 2025.
  • Biggest five-year swings in Short term Debt: skyrocketed 77.78% in 2022 and later crashed 94.69% in 2025.
  • Year by year, Short term Debt stood at $88000.0 in 2021, then crashed by 80.68% to $17000.0 in 2022, then skyrocketed by 594.12% to $118000.0 in 2024, then crashed by 68.64% to $37000.0 in 2025.
  • Business Quant data shows Short term Debt for GTHP at $37000.0 in Q4 2025, $79000.0 in Q3 2025, and $60000.0 in Q2 2025.